Interleukin-27 inhibits the growth of pediatric acute myeloid leukemia in NOD/SCID/Il2rg -/- mice

Clinical Cancer Research

Volumn 18, Issue 6, 2012, Pages 1630-1640

  Zorzoli, Alessia ^a   Di Carlo, Emma ^c   Cocco, Claudia ^a   Ognio, Emanuela ^b   Ribatti, Domenico ^d   Ferretti, Elisa ^a   Dufour, Carlo ^a   Locatelli, Franco ^e,f   Montagna, Daniela ^f   Airoldi, Irma ^a  

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

^d UNIVERSITY OF BARI   (Italy)

^e BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^f UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN; ANGIOPOIETIN 2; ANGIOPOIETIN 3; CD19 ANTIGEN; CD3 ANTIGEN; CD33 ANTIGEN; CD45 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; CXCL1 CHEMOKINE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GELATINASE A; GELATINASE B; GLYCOPROTEIN GP 130; GRANULOCYTE CHEMOTACTIC PROTEIN 2; HUMAN RECOMBINANT INTERLEUKIN 17; INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 6; KI 67 ANTIGEN; LIPOCORTIN 5; MATRILYSIN; RETICULIN; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN C; WSX 1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ANGIOPOIETIN 2 GENE; ANGIOPOIETIN 3 GENE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CDH6 GENE; CELL ASSAY; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CHILD; CHILDHOOD LEUKEMIA; CHORIOALLANTOIC MEMBRANE ASSAY; CLINICAL ARTICLE; CONTROLLED STUDY; CXCL1 GENE; CXCL10 GENE; CXCL5 GENE; CXCL6 GENE; CXCR4 GENE; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; IFN GAMMA GENE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INTERLEUKIN 6 GENE; LEUKEMIA CELL; MALE; MATRIX METALLOPROTEINASE 7 GENE; MICROVASCULARIZATION; MMP2 GENE; MMP9 GENE; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SCID MOUSE; STAINING; TIMP2 GENE; UPREGULATION; VEGF C GENE;

ADOLESCENT; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INTERLEUKIN-17; LEUKEMIA, MYELOID, ACUTE; MALE; MICE; MICE, INBRED NOD; MICE, SCID; NEOVASCULARIZATION, PATHOLOGIC; XENOGRAFT MODEL ANTITUMOR ASSAYS; YOUNG ADULT;

EID: 84858233334     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2432     Document Type: Article

References (49)

1. Trinchieri G, Pflanz S, Kastelein RA. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity 2003;19:641-4. (Pubitemid 37490789)
2. Pflanz S, Timans JC, Cheung J, Rosales R, Kanzler H, Gilbert J, et al. IL- 27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells. Immunity 2002;16:779-90. (Pubitemid 34786477)
3. Hisada M, Kamiya S, Fujita K, Belladonna ML, Aoki T, Koyanagi Y, et al. Potent antitumor activity of interleukin-27. Cancer Res 2004;64:1152-6. (Pubitemid 38176923)
4. Stumhofer JS, Laurence A, Wilson EH, Huang E, Tato CM, Johnson LM, et al. Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat Immunol 2006;7:937-45. (Pubitemid 44263907)
5. Chen Q, Ghilardi N, Wang H, Baker T, Xie MH, Gurney A, et al. Development of Th1-type immune responses requires the type I cytokine receptor TCCR. Nature 2000;407:916-20.
6. Pflanz S, Hibbert L, Mattson J, Rosales R, Vaisberg E, Bazan JF, et al. WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J Immunol 2004;172:2225-31. (Pubitemid 38182370)
7. Canale S, Cocco C, Frasson C, Seganfreddo E, Di Carlo E, Ognio E, et al. Interleukin-27 inhibits pediatric B-acute lymphoblastic leukemia cell spreading in a pre-clinical model. Leukemia 2011;25:1815-24.
8. Cocco C, Giuliani N, Di Carlo E, Ognio E, Storti P, Abeltino M, et al. Interleukin-27 acts as multifunctional antitumor agent in multiple myeloma. Clin Cancer Res 2010;16:4188-97.
9. Oniki S, Nagai H, Horikawa T, Furukawa J, Belladonna ML, Yoshimoto T, et al. Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma. Cancer Res 2006;66:6395-404.
10. Shimizu M, Shimamura M, Owaki T, Asakawa M, Fujita K, Kudo M, et al. Antiangiogenic and antitumor activities of IL-27. J Immunol 2006;176:7317-24. (Pubitemid 43849032)
11. Airoldi I, Di Carlo E, Banelli B, Moserle L, Cocco C, Pezzolo A, et al. The IL-12Rbeta2 gene functions as a tumor suppressor in human B cell malignancies. J Clin Invest 2004;113:1651-9. (Pubitemid 39071689)
12. Airoldi I, Di Carlo E, Cocco C, Caci E, Cilli M, Sorrentino C, et al. IL- 12 can target human lung adenocarcinoma cells and normal bronchial epithelial cells surrounding tumor lesions. PLoS One 2009;4:e6119.
13. Airoldi I, Di Carlo E, Cocco C, Taverniti G, D'Antuono T, Ognio E, et al. Endogenous IL-12 triggers an antiangiogenic program in melanoma cells. Proc Natl Acad Sci U S A 2007;104:3996-4001. (Pubitemid 47181567)
14. Airoldi I, Cocco C, Giuliani N, Ferrarini M, Colla S, Ognio E, et al. Constitutive expression of IL-12R beta 2 on human multiple myeloma cells delineates a novel therapeutic target. Blood 2008;112:750-9.
15. Yoshimoto T, Morishima N, Mizoguchi I, Shimizu M, Nagai H, Oniki S, et al. Antiproliferative activity of IL-27 on melanoma. J Immunol 2008;180:6527-35.
16. Ho MY, Leu SJ, Sun GH, Tao MH, Tang SJ, Sun KH. IL-27 directly restrains lung tumorigenicity by suppressing cyclooxygenase-2-mediated activities. J Immunol 2009;183:6217-26.
17. Stone RM, O'Donnell MR, Sekeres MA. Acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2004;98-117.
18. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292-302.
19. Kaspers GJ, Zwaan CM. Pediatric acute myeloid leukemia: towards high-quality cure of all patients. Haematologica 2007;92:1519-32. (Pubitemid 350144128)
20. Shah M, Agarwal B. Recent advances in management of acute myeloid leukemia (AML). Indian J Pediatr 2008;75:831-7.
21. Ravandi F. Role of cytokines in the treatment of acute leukemias: a review. Leukemia 2006;20:563-71.
22. Lange BJ, Yang RK, Gan J, Hank JA, Sievers EL, Alonzo TA, et al. Soluble interleukin-2 receptor alpha activation in a Children's Oncology Group randomized trial of interleukin-2 therapy for pediatric acute myeloid leukemia. Pediatr Blood Cancer 2011;57:398-405.
23. Ribatti D, Gualandris A, Bastaki M, Vacca A, Iurlaro M, Roncali L, et al. New model for the study of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane: the gelatin sponge/chorio-allantoic membrane assay. J Vasc Res 1997;34:455-63. (Pubitemid 28008032)
24. Larousserie F, Charlot P, Bardel E, Froger J, Kastelein RA, Devergne O. Differential effects of IL-27 on human B cell subsets. J Immunol 2006;176:5890-7.
25. Agliano A, Martin-Padura I, Mancuso P, Marighetti P, Rabascio C, Pruneri G, et al. Human acute leukemia cells injected in NOD/LtSz-scid/ IL-2Rgamma null mice generate a faster and more efficient disease compared to other NOD/scid-related strains. Int J Cancer 2008;123:2222-7.
26. Ferretti E, Montagna D, Di Carlo E, Cocco C, Ribatti D, Ognio E, et al. Absence of IL-12Rbeta2 in CD33(+)CD38(+) pediatric acute myeloid leukemia cells favours progression in NOD/SCID/IL2RgammaC-deficient mice. Leukemia 2011;doi:10.1038/leu.2011.213.
27. Crǎ;iţoiu S. The morphopathological aspects of diabetic retinopathy. Oftalmologia 1992;36:141-8.
28. Garner A. Histopathology of diabetic retinopathy in man. Eye (Lond) 1993;7:250-3. (Pubitemid 23153118)
29. Tavor S, Petit I. Can inhibition of the SDF-1/CXCR4 axis eradicate acute leukemia? Semin Cancer Biol 2010;20:178-85.
30. Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 2006;107:1761-7. (Pubitemid 43289351)
31. Burger JA, Peled A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia 2009;23:43-52.
32. Villarino AV, Hunter CA. Biology of recently discovered cytokines: discerning the pro- and anti-inflammatory properties of interleukin-27. Arthritis Res Ther 2004;6:225-33. (Pubitemid 40124374)
33. Chiyo M, Shimozato O, Yu L, Kawamura K, Iizasa T, Fujisawa T, et al. Expression of IL-27 in murine carcinoma cells produces antitumor effects and induces protective immunity in inoculated host animals. Int J Cancer 2005;115:437-42. (Pubitemid 40663748)
34. Pradhan A, Lambert QT, Reuther GW. Transformation of hematopoietic cells and activation of JAK2-V617F by IL-27R, a component of a heterodimeric type I cytokine receptor. Proc Natl Acad Sci U S A 2007;104:18502-7. (Pubitemid 350210726)
35. Castor A, Nilsson L, Astrand-Grundstrom I, Buitenhuis M, Ramirez C, Anderson K, et al. Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia. Nat Med 2005;11:630-7. (Pubitemid 40868303)
36. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efficient tumour formation by single human melanoma cells. Nature 2008;456:593-8.
37. Loges S, Heil G, Bruweleit M, Schoder V, Butzal M, Fischer U, et al. Analysis of concerted expression of angiogenic growth factors in acute myeloid leukemia: expression of angiopoietin-2 represents an independent prognostic factor foroverallsurvival.JClinOncol2005;23:1109-17. (Pubitemid 46202266)
38. Schliemann C, Bieker R, Thoennissen N, Gerss J, Liersch R, Kessler T, et al. Circulating angiopoietin-2 is a strong prognostic factor in acute myeloid leukemia. Leukemia 2007;21:1901-6. (Pubitemid 47299962)
39. Strieter RM, Burdick MD, Mestas J, Gomperts B, Keane MP, Belperio JA. Cancer CXC chemokine networks and tumour angiogenesis. Eur J Cancer 2006;42:768-78.
40. Kittang AO, Hatfield K, Sand K, Reikvam H, Bruserud O. The chemokine network in acute myelogenous leukemia: molecular mechanisms involved in leukemogenesis and therapeutic implications. Curr Top Microbiol Immunol 2010;341:149-72.
41. Akashi K, Harada M, Shibuya T, Eto T, Takamatsu Y, Teshima T, et al. Effects of interleukin-4 and interleukin-6 on the proliferation of CD34+and CD34- blasts from acute myelogenous leukemia. Blood 1991;78:197-204.
42. Ferretti E, Di Carlo E, Cocco C, Ribatti D, Sorrentino C, Ognio E, et al. Direct inhibition of human acute myeloid leukemia cell growth by IL-12. Immunol Lett 2010;133:99-105.
43. Koshiba T, Hosotani R, Miyamoto Y, Ida J, Tsuji S, Nakajima S, et al. Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression. Clin Cancer Res 2000;6:3530-5.
44. Shimazui T, Yoshikawa K, Uemura H, Hirao Y, Saga S, Akaza H. The level of cadherin-6mRNAin peripheral blood is associatedwith the site of metastasis and with the subsequent occurrence of metastases in renal cell carcinoma. Cancer 2004;101:963-8. (Pubitemid 39100429)
45. Reikvam H, Hatfield KJ, Oyan AM, Kalland KH, Kittang AO, Bruserud O. Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation. Eur J Haematol 2010;84:239-51.
46. Jacobi A, Thieme S, Lehmann R, Ugarte F, Malech HL, Koch S, et al. Impact of CXCR4 inhibition on FLT3-ITD-positive human AML blasts. Exp Hematol 2010;38:180-90.
47. Tavor S, Eisenbach M, Jacob-Hirsch J, Golan T, Petit I, Benzion K, et al. The CXCR4 antagonist AMD3100 impairs survival of human AML cells and induces their differentiation. Leukemia 2008;22:2151-5158.
48. Scupoli MT, Perbellini O, Krampera M, Vinante F, Cioffi F, Pizzolo G. Interleukin 7 requirement for survival of T-cell acute lymphoblastic leukemia and human thymocytes on bone marrow stroma. Haematologica 2007;92:264-6. (Pubitemid 46860199)
49. Seita J, Asakawa M, Ooehara J, Takayanagi S, Morita Y, Watanabe N, et al. Interleukin-27 directly induces differentiation in hematopoietic stem cells. Blood 2008;111:1903-12. (Pubitemid 351451499)